UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

The Lancet (British edition), 2010-04, Vol.375 (9724), p.1437-1446

2010

Volltextzugriff (PDF)

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

The Lancet (British edition), 2008-07, Vol.372 (9634), p.207-215

2008

Volltextzugriff (PDF)

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Journal of vascular surgery, 2006-04, Vol.43 (4), p.742-751.e1

2006

Volltextzugriff (PDF)

Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial

Journal of vascular surgery, 2005-09, Vol.42 (3), p.456-464

2005

Volltextzugriff (PDF)

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The New England journal of medicine, 2012-09, Vol.367 (13), p.1187-1197

2012

Volltextzugriff (PDF)

Prolonged treatment of human osteoarthritic chondrocytes with insulin-like growth factor-I stimulates proteoglycan synthesis but not proteoglycan matrix accumulation in alginate cultures

Journal of rheumatology, 2003-07, Vol.30 (7), p.1565

2003

Volltextzugriff (PDF)

Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia

Journal of vascular surgery, 2006-11, Vol.44 (5), p.977-983

2006

Volltextzugriff (PDF)

Conducting an Alzheimer's clinical trial in Russia

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P171-P171

Seely, Lynn

2009

Volltextzugriff (PDF)

F5‐01‐04: Conducting an Alzheimer's clinical trial in Russia

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_6), p.P171-P171

Seely, Lynn

2009

Volltextzugriff (PDF)

Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo

BMC cancer, 2002-05, Vol.2 (1), p.15-15, Article 15

2002

Volltextzugriff (PDF)

Protein tyrosine phosphatase 1B interacts with the activated insulin receptor

Diabetes (New York, N.Y.), 1996-10, Vol.45 (10), p.1379

1996

Volltextzugriff (PDF)

Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

Vascular and endovascular surgery, 2005-01, Vol.39 (1), p.15-23

2005

Volltextzugriff (PDF)

Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology

The Journal of nutrition, health & aging, 2012-04, Vol.16 (4), p.339-345

2012

Volltextzugriff (PDF)

Localization of the Insulin-like Growth Factor I Receptor Binding Sites for the SH2 Domain Proteins p85, Syp, and GTPase Activating Protein

The Journal of biological chemistry, 1995-08, Vol.270 (32), p.19151-19157

1995

Volltextzugriff (PDF)

O3‐13‐06: Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials

Alzheimer's & dementia, 2012-07, Vol.8 (4S_Part_12), p.P456-P456

2012

Volltextzugriff (PDF)

Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials

Alzheimer's & dementia, 2012-07, Vol.8 (4), p.P456-P456

2012

Volltextzugriff (PDF)

Statistical treatment of withdrawal in trials of anti-dementia drugs – Authors' reply

The Lancet (British edition), 2008, Vol.372 (9647), p.1383-1383

2008

Volltextzugriff (PDF)

Statistical treatment of withdrawal in trials of anti-dementia drugs/Authors' reply

The Lancet (British edition), 2008-10, Vol.372 (9647), p.1382

2008

Volltextzugriff (PDF)

S4‐01‐02: Results from CONNECTION: A global, Phase 3 double‐blind, placebo‐controlled confirmatory trial of dimebon (latrepirdine) in patients with mild‐to‐moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_5), p.S147-S147

2010

Volltextzugriff (PDF)

Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S147-S147

2010

Volltextzugriff (PDF)

A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P251-P251

2009

Volltextzugriff (PDF)

P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_8), p.P251-P251

2009

Volltextzugriff (PDF)

Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.CN02-03-CN02-03

2009

Volltextzugriff (PDF)

P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T770-T771

2008

Volltextzugriff (PDF)

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease : sa randomised, double-blind, placebo-controlled study. Commentary

The Lancet (British edition), 2008, Vol.372 (9634)

2008

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Biological And Medical Sciences
(15)
Medical Sciences
(12)
Animals
(10)
Neurology
(10)
Aged
(8)
Female
(8)
Male
(7)
Middle Aged
(7)
Rats
(7)
Biochemistry & Molecular Biology
(6)
Double-Blind Method
(6)
Receptor, Insulin - Metabolism
(6)
Molecular Sequence Data
(5)
Treatment Outcome
(5)
Adult
(4)
Blood. Blood Coagulation. Reticuloendothelial System
(4)
Cell Line
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Prolonged treatment of human osteoarthritic chondrocytes with insulin-like growth factor-I stimulates proteoglycan synthesis but not proteoglycan matrix accumulation in alginate cultures

Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia

Conducting an Alzheimer's clinical trial in Russia

F5‐01‐04: Conducting an Alzheimer's clinical trial in Russia

Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo

Protein tyrosine phosphatase 1B interacts with the activated insulin receptor

Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology

Localization of the Insulin-like Growth Factor I Receptor Binding Sites for the SH2 Domain Proteins p85, Syp, and GTPase Activating Protein

O3‐13‐06: Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials

Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials

Statistical treatment of withdrawal in trials of anti-dementia drugs – Authors' reply

Statistical treatment of withdrawal in trials of anti-dementia drugs/Authors' reply

S4‐01‐02: Results from CONNECTION: A global, Phase 3 double‐blind, placebo‐controlled confirmatory trial of dimebon (latrepirdine) in patients with mild‐to‐moderate Alzheimer's disease

Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease

A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100

P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease : sa randomised, double-blind, placebo-controlled study. Commentary

Suchergebnisse filtern